Carotid Stenosis under Strontium Ranelate |Biomedgrid

Strontium ranelate (RS) occupies a place in the therapeutic arsenal of osteoporosis. It has been granted Marketing Authorization (MA) for the treatment of postmenopausal osteoporosis since January 2006. Its anti-fracture efficacy is at least equal to that of bisphosphonates. If some side effects are frequent and not severe, the serious risks of venous thromboembolism and DRESS are less frequent. Arterial accidents are exceptional. We report a case of internal carotid artery stenosis that occurred three years after treatment with strontium ranelate in a 76-year-old woman treated for non-active rheumatoid arthritis. Indeed in view of the side effects, RS was suspended.